ANKTIVA's sBLA expansion into BCG-naïve NMIBC CIS will determine whether a commercially validated IL-15 superagonist can capture the larger treatment-naive bladder cancer market

Bull

A positive outcome would be FDA acceptance and approval of the sBLA supported by QUILT-2.005 data showing a complete response rate and durability profile that meets or exceeds the historical BCG benchmark in BCG-naïve CIS patients — typically a 12-month CR rate above 70–75%. Approval would expand ANKTIVA's label to the BCG-naïve population, which is substantially larger than the BCG-unresponsive segment, dramatically widening the addressable market and validating the IL-15 superagonist mechanism as a frontline standard of care in NMIBC.

Bear

The most likely failure mode is a CR rate or durability profile that fails to demonstrate non-inferiority or superiority to BCG monotherapy in a treatment-naive population that already responds reasonably well to BCG alone, making the risk-benefit case for combination therapy unclear to FDA. A second risk is that FDA requests additional follow-up data before approving a BCG-naïve indication, given that BCG-naïve patients have a more favorable natural history, potentially raising the evidentiary bar and delaying the regulatory decision significantly.